| Identification | Back Directory | [Name]
2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoicacid | [CAS]
890842-28-1 | [Synonyms]
CS-1142
GSK 650394
GSK650394 (Free base)
SGK inhibitor GS650394
2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoicacid
Benzoic acid, 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- | [Molecular Formula]
C25H22N2O2 | [MDL Number]
MFCD12828779 | [MOL File]
890842-28-1.mol | [Molecular Weight]
382.45 |
| Hazard Information | Back Directory | [Uses]
GSK-650394 has been used as a serum and glucocorticoid-activated kinase (SGK1) inhibitor. | [Definition]
ChEBI: 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid is a phenylpyridine. | [Biochem/physiol Actions]
GSK-650394 has an IC50 value of 62?nM for serum and glucocorticoid-activated kinase-1 (SGK1) and 103?nM for SGK2. It has an ability to stop viral replication at concentrations that are nontoxic to cells. | [in vivo]
GSK650394 (1, 10, and 30 μM, 10 μL/rat, intrathecally) dose-dependently prevents CFA-induced pain behavior and the associates SGK1 phosphorylation, GluR1 trafficking, and protein-protein interactions at 1 day after CFA administration[3]. GSK650394 at concentrations of 10, 30, and 100 nM (10 μL), but not vehicle solution (SNL 3D+Veh and SNL 7D+Veh, respectively), dose-dependently increases the withdrawal latency of the ipsilateral hindpaw at 1-3 and 1-5 h after injection at days 3 and 7 postsurgery (SNL 3D+GSK and SNL 7D+GSK, respectively). GSK650394 (from day 0 to 6 postsurgery; 100 nM, 10 μL, i.t.) administration alleviates SNL-induced allodynia at days 3, 5, and 7 postsurgery in SNL animals[4]. | [IC 50]
SGK1 | [storage]
Store at RT |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList13285/0.htm |
|